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This study was performed to investigate the biological
effects of boron neutron capture therapy (BNCT) on the
testes and eyes in mice using HANARO Nuclear Reactor,
Korea Atomic Energy Research Institute. BNCT relies on
the high capacity of 
10B in capturing thermal neutrons.
Sodium borocaptate (BSH, 75 ppm, iv) and borono-
phenylalanine (BPA, 750 ppm, ip) have been used as the
boron delivery agents. Mice were irradiated with neutron
(flux: 1.036739E +09, Fluence 9.600200E+12) by lying flat
pose for 30 (10 Gy) or 100 min (33 Gy) with or without
boron carrier treatment. In 45 days of irradiation,
histopathological changes of the testes and eyes were
examined. Thirty-three Gy neutron irradiation for 100 min
induced testicular atrophy in which some of seminiferous
tubules showed complete depletion of spermatogenic
germ cells. Lens epithelial cells and lens fiber were swollen
and showed granular changes in an exposure time
dependent manner. However, boron carrier treatment had
no significant effect on the lesions. These results suggest
that the examination of histopathological changes of lens
and testis can be used as “biological dosimeters” for
gauging radiation responses and the HANARO Nuclear
Reactor has sufficient capacities for the BNCT.
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Introduction
In cancer treatment, surgery, radiation therapy and
chemotherapy are good standard procedure, but there are
still many treatment failures. An ideal therapy for cancer
would be destroying all tumor cells selectively without
damaging normal tissues. The boron neutron capture
therapy (BNCT) which had been recently developed has
given great promise in cancer therapy with minimum side
effects [1]. The effectiveness of BNCT depends on the
relative high concentrations of 
10B in tumor compared with
the surrounding normal tissues. It is assumed that the 
10B-
containing compounds selectively accumulated in cancer
cells will cause preferential killing of the cells and result in
therapeutic effects [22]. When the boron compounds are
exposed to thermal neutrons, they release two high linear
energy transfer (LET) particles, an α(
4He) particle and a
lithium (
7Li) recoil nucleus to the cells in which they
accumulate. These particles from the 
10B (n, α)
7Li reaction
have extremely short path lengths (5~10 µm) in water [16].
Capture of neutron by 
10B, a stable isotope, results in the
formation of excited boron-11 (
11B). The unstable 
11B
instantly reacts to yield the high linear energy transfer (LET)
lithium-7 (
7Li) and energetic α-particles (
4He). The kinetic
energy of 
7Li and α particles is about 2.8 million electron
volts (eV) (100 million times more than what was put in).
Along with high linear energy transfer (LET) makes the
particles highly toxic to the cells [22]. The short range of
these heavy particles (5-9 µm) and 
10B accumulation in
target tissues provide great advantage in selective tumor
destruction without significant damage to the surrounding
normal tissues [7]. Two boron drugs have been used clinically,
sodium borocaptate (BSH, Na(2)B(12)H(11)SH) and a
dihydroxyboryl derivative of phenylalanine called borono-
phenylalanine (BPA) [8,13,15].
Neutron sources for BNCT are limited to nuclear reactors
that are available in a few countries, including the United
States, Japan, several European countries, and Argentina.
Clinical trials using the apparatus have been carried out in
Japan, Europe, and the United States. The HANARO
Nuclear Reactor has been recently installed in the Korea
Atomic Energy Research Institute. The factors influencing
beam performance, such as the neutron energy spectrum,
field size and degree of collimation, are not identical in each
reactor [3]. In addition, the values of the parameters to
calculate a dose vary with different biological and/or
medical circumstances, boron delivery agents, dose of
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neutron, and differences in beam designs. These issues
should be adequately addressed in the clinical trials of
BNCT. In the present study, we investigated the histo-
phathological changes of testes and eyes of mice by neutron
irradiation with or without boron treatment in mice as a first
step for the investigation of biological effects of BNCT
using the HANARO Nuclear Reactor.
Materials and Methods
Animals
C57BL/6 male mice (22 ± 2 g ) were received at 6 weeks
of age from Daehan Biolink (Eumseong, Korea). They were
maintained under specific pathogen-free conditions and fed
sterilized food and water ad libitum.
Boron compounds
Two boron compounds, BPA and BSH, were purchased
from Ryscor science (USA). The aqueous solution of BPA
was prepared at concentration of 750 ppm and injected
intraperitoneally 3 hours before irradiation. BSH was
dissolved in physiological saline at a concentration of 75
ppm and injected into caudal vein 1 hour before irradiation.
Neutron Irradiation
Fifteen mice were divided to five experimental groups.
Neutron was irradiated with or without boron treatment
(Table 1). Prior to each irradiation, all animals were
anesthetized with 0.2 ml of 1% chloral hydrate (Fluka,
Japan). They were irradiated by 10 or 33 Gy neutron (flux:
1.036739E+09, Fluence 9.600200E+12) with lying flat pose
for 30 or 100 min using BNCT facility on HANARO
Nuclear Reactor.
Histopathology
Mice were sacrificed at 45 days after irradiation. Testes
were fixed in Bouin’s fluid (picric acid, saturated aqueous
sol. 75 ml, formalin 25 ml, glacial acetic acid 5 ml), and
after 24 hours stored in 70% ethanol. Eyes were fixed in
Davidson’s fixatives (ethyl alcohol 30 ml, formalin 20 ml,
glacial acetic acid 10 ml). Samples were dehydrated in 50%
to 100% alcohol, and xylene was used for clearing samples.
Tissues were embedded in paraffin, sectioned (5 µm thick),
stained with H&E, and examined with light microscope.
Results
Histopathological changes
Testes: There were no notable changes of seminiferous
tubules of the mice in group 1 and 2 (Fig. 1). In groups 3, 4
and 5, moderate atrophy of seminiferous tubules was
observed in the testes. Atrophic seminiferous tubules are
lined with only Sertoli cells or with a few germ cells (Fig. 2).
The damaged seminiferous tubules were observed mainly in
the periphery of the testicles. However, other seminiferous
tubules showed normal spermatogenesis with only a few
germ cells degeneration. BPA and BSH had no significant
effect on the lesions (Figs. 3 and 4).
Table 1. Experimental design
Group* Treatment
1 Non irradiated control 
2 10 Gy neutron irradiation for 30 min
3 33 Gy neutron irradiation for 100 min
4 33 Gy neutron irradiation for 100 min in 
combination with BPA
5 33 Gy neutron irradiation for 100 min in 
combination with BSH
*Three mice were in each experimental group.
Fig. 2. Seminiferous tubules from the mouse irradiated with 33
Gy neutron for 100 min. Some tubules are lined Sertoli cells wit h
a few germ cells. H&E stain, ×200.
Fig. 1. Seminiferous tubules from the control mouse testis
containing normal spermatogenic germ cells. H&E stain, ×200.Histopathological changes of testes and eyes by neutron irradiation with boron compounds in mice 21
Eyes: The nucleated lens fibers below the single layer of
cuboidal epithelium showed normal histology in the
specimens obtained from the mice in groups 1 and 2 (Fig.
5). Lens epithelial cells and lens fibers were swollen and
showed granular changes and a few vacuoles in groups 3, 4
and 5 (Figs. 6, 7 and 8). Only one mouse in group 5 showed
more severe damages the eyes.
Discussion
In the present study, histopathological changes of eyes and
testis were assessed in 45 days of neutron irradiation with or
without pretreatment of boron compounds in mice. It has
been reported that irradiation induces several histo-
pathological consequences in the organs and tissues,
including the increase of loose fibrous tissues, infiltration of
macrophages and polymorphonuclear leukocytes, and
vacuolation of epithelial cells in the choroid plexus,
desquamation of the skin and ocular changes consisting of
keratitis, blepharitis, conjunctivitis, cataract formation, and
morphological changes in retina [11,14,21]. Our study
demonstrates that 33 Gy neutron irradiation for 100 min
induced cataract in eyes of the mouse, although it was
Fig. 3. Seminiferous tubules from the mouse pretreated wit h
boronophenylalanine and irradiated with 33 Gy neutron for 100
min. Seminiferous tubules are lined Sertoli cells with a few germ
cells. H&E stain, ×200.
Fig. 4. Seminiferous tubules from the mouse pretreated wit h
sodium borocaptate and irradiated with 33 Gy neutron for 100
min. Some seminiferous tubules are lined Sertoli cells with a fe w
germ cells. H&E stain, ×200.
Fig. 5. Lens from the control mouse eye. Note the nucleated lens
fibers below the single layer of cuboidal epithelium. H&E stain,
×400.
Fig. 6. Lens from the mouse irradiated with 33 Gy neutron fo r
100 min. Lens epithelial cells and lens fiber are swollen an d
showing granular changes H&E stain, ×400.
Fig. 7. Lens from the mouse pretreated with borono-
phenylalanine and irradiated with 33 Gy neutron for 100 min.
Lens epithelial cells and lens fiber are swollen and showing
granular changes and a few vacuoles are evident. H&E stain,
×400.
Fig. 8. Lens from the mouse pretreated with sodium borocaptate
and irradiated with 33 Gy neutron for 100 min. Lens epithelial
cells and lens fiber are swollen and showing granular changes
and a few vacuoles are evident. H&E stain, ×400.22 Yeon-Joo Kim et al.
predicted the threshold dose that may cause damage to
retinal structures is 250 cGy [11]. Thirty three Gy neutron
did not induce other ocular lesions such as retinal changes
and keratitis. Due to the geometry of the mouse’s head, the
eyes were close to the center of the collimated beam, and
would have received a significant radiation dose [14]. Other
parameters, such as examination methods, exposure time,
dose of neutron, and differences in beam designs, may be
related to the results. Since the lens have been recognized as
a “biological dosimeter” for gauging radiation responses, a
standardized methodology of appraisal of eye lesions has to
be established.
The testis is also a main target organ of irradiation
damage. In the this study, a severe tubular atrophy with
complete loss of germ cells was noted in some seminiferous
tubules in the mice irradiated with neutron for 100 min.
However, other tubules showed normal spermatogenesis
with degenerating germ cells within a normal range. This
result indicates the spermatogonial damages by neutron
could induce permanent impairment of spermatogenesis.
The most neutron-sensitive spermatogenic germ cells are
spermatogonia when the majority of these cells are in G0
phase. However, the cells are most resistant when they are
stimulated for proliferation, and exhibit intermediate
sensitivities during active proliferation [20]. Spermatogonial
depletion by testicular toxicants results in seminiferous
tubules atrophy by impairment of spermatogenesis [18]. In
addition, 30 min neutron irradiation did not induce
histopathological changes in the eyes and testes. Further
studies on time-cause observation of spermatogenesis and
ocular changes immediately after irradiation are required in
order to investigate this.
BNCT is a binary system for treatment of cancers which is
based on absorption of low-energy neutrons by nonradioactive
boron-10 (
10B) atoms delivered to neoplastic cells in the
form of a boron carrying drug [2,6,10,22]. Over the past 20
years, many classes of boron-containing compounds have
been designed and synthesized. Those compounds include
boron-containing amino acids, biochemical precursors of
nucleic acids, DNA-binding molecules, porphyrin derivatives,
high molecular weight delivery agents such as monoclonal
antibodies and their fragments that recognize a tumor-
associated epitopes, such as epidermal growth factor, and
liposomes. Two 
10B delivery agents, amino acid p-borono-
phenylalanine (BPA) and sulfhydryl borane (BSH), are
being used in current clinical protocols for the treatment of
cancers [7]. BSH, which was developed by Soloway [17],
has been applied in malignant glioma patients in Japan [9].
Subsequently, BPA, a melanin precursor, was developed for
BNTC of melanomas and is in clinical trials as a neutron
capture agent in glioma patients [4,12].
This study shows that neutron irradiation induced testis
atrophy and lens degeneration in a time and dose-dependent
manner. However, boron carriers, BPA and BSH had no
significant effect on the lesions, except one case of mouse
showing more severe lesions in the lens by BPA. Studies
have been carried out in both normal and neoplastic tissues
to characterize the relative biological effectiveness of each
radiation component. The distribution patterns and radio-
biological characteristics of the two 
10B delivery agents in
current clinical use have been evaluated in a range of normal
tissues and tumor types [5]. Wide range of differences in the
distribution of the 
10B-labeled compound in tissues have
been reported [19]. In addition, BPA or BSH are mutagenic
and the retention of these boron compounds in the cells
causes accurate assaults on the cell and lessens the chance of
misrepair after neutron irradiation [13]. These previous
reports have been warranted further studies on toxicological
effects in other organs under various experimental conditions.
In conclusion, 33Gy (flux: 1.036739E+09, Fluence
9.600200E+12) neutron with lying flat pose in mice,
induced atrophy of some seminiferous tubules and swelling,
vacuolation and granular changes of lens epithelial cells and
lens fiber in an exposure time dependent manner in mice. In
addition, Pretreatment of boron carriers, BSH or BPA had
no significant effect on the lesions. These data demonstrated
that histopathological changes of lens and testis could be
used as “biological dosimeters” for gauging radiation responses
and the HANARO Nuclear Reactor has sufficient capacity
for the BNCT. Further investigations regarding the precise
dose distribution and a wide range of preclinical studies
should be conducted for human clinical trials.
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